Neupogen and mesenchymal stem cells are the novel therapeutic agents in regeneration of induced endometrial fibrosis in experimental rats
| Autor: | Abeer Mostafa, Ayman Hassan, Ashraf A. Shamaa, Hanan Ali, Samar Marzouk, Walaa Ibrahim, Dina Sabry |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Filgrastim
medicine.drug_class medicine.medical_treatment Biophysics Mesenchymal Stem Cell Transplantation Biochemistry 03 medical and health sciences chemistry.chemical_compound Endometrium 0302 clinical medicine Neuopogen Fibrosis medicine Animals Regeneration Rats Wistar Molecular Biology Research Articles mesenchymal stem cell Uterine Diseases 030219 obstetrics & reproductive medicine business.industry Growth factor Mesenchymal stem cell Interleukin Estrogens Mesenchymal Stem Cells Cell Biology medicine.disease Rats CTGF Vascular endothelial growth factor Disease Models Animal chemistry Estrogen 030220 oncology & carcinogenesis Immunology Cancer research Female Stem cell business endometrial fibrosis Biomarkers Research Article |
| Zdroj: | Bioscience Reports |
| ISSN: | 1573-4935 0144-8463 |
| Popis: | Endometrial fibrosis is the presence of intrauterine adhesions (IUAs) after any uterine surgery or curettage and it results in infertility and recurrent pregnancy loss. We evaluated the role of human mesenchymal stem cells (hMSCs) as a therapeutic agent of endometrial fibrosis. We also compared the effect of MSCs with the effect of estrogen and neupogen either each alone or as a combined therapy with MSCs. This experimental study was performed on 84 albino rats which were divided into seven groups (n=12 rats/group) as follows, group1: normal control rats, group 2: induced fibrosis, group 3: induced fibrosis that received oral estrogen, group 4: induced fibrosis that received hMSCs, group 5: induced fibrosis that received hMSCs and estrogen, group 6: induced fibrosis that received neupogen, and group 7: induced fibrosis that received hMSCs and neupogen. The extent of fibrosis, vascularization, and inflammation were evaluated by; qRT-PCR for interleukin 1 (IL-1), interleukin 6 (IL-6), TNF, vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), and RUNX; ELISA for connective tissue growth factor (CTGF); Western blotting for collagen-I; immunohistochemistry examination for VEGF and RUNX-2; and histopathological assessment. In therapeutic groups either by hMSCs alone or combined with estrogen or neupogen; fibrosis and inflammation (IL-1, IL-6, TNF, TGF-β, RUNX, CTGF, and collagen-I) were significantly decreased but vascularization (VEGF) was significantly increased (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|